Alpine Immune Sciences Appoints Wolfgang Dummer To Succeed Andrew Sandler As Chief Medical Officer
(RTTNews) - Alpine Immune Sciences, Inc. (ALPN), a clinical-stage immunotherapy company, announced Wednesday the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023.
Dummer succeeds Andrew Sandler, M.D., who will transition responsibilities to Dummer through the remainder of the year.
Dummer brings over 20 years of global drug development leadership experience and has led the development of multiple drug approvals in immunology and rare diseases. He joins Alpine from Rigel Pharmaceuticals, where he served as Chief Medical Officer.
Prior to his time at Rigel, Dummer served as Vice President of Clinical Development at BioMarin, and previously held various roles of increasing responsibility at Genentech where he was Global Development Leader for ocrelizumab and rituximab.
In conjunction with his employment, effective October 2, 2023, Dummer has been granted an option to purchase 200,000 shares of common stock.
Euro Climbs Against Majors
Swiss Market Ends Marginally Up
European Stocks Close Weak
Canadian Stocks Turning In Mixed Performance; TSX Down Marginally
U.S. Pending Home Sales Fall More Than Expected In July
Eurozone Economic Confidence Weakens In August
Walgreen Co. Now Operating As Private Standalone Company Under Sycamore Partners
